JNJ vs QCOM: Which Is the Better Buy?

Side-by-side comparison of Johnson & Johnson and QUALCOMM Incorporated — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-20.
Johnson & Johnson · Healthcare
$230.69
+10.8% upside to fair value
Grade C High Quality
VS
QUALCOMM Incorporated · Technology
$134.47
+45.0% upside to fair value
Med Conviction Grade B
QuantHub Verdict
QCOM has more upside to fair value (+45.0%). QCOM trades at a lower forward P/E (26.8x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric JNJ QCOM
Current Price $230.69 $134.47
Fair Value Estimate $255.61 $194.98
Upside to Fair Value +10.8% +45.0%
Market Cap $555.9B $143.6B
Forward P/E 26.8x 26.8x
EV / EBITDA 18.5x
Price / Sales 5.8x 3.2x
Price / FCF 28.2x 11.1x
Revenue Growth YoY +9.9% +8.7%
Gross Margin 69.1% 55.1%
Operating Margin 26.9% 27.1%
Return on Equity 26.5% 21.6%
Dividend Yield 0%
FCF Yield 3.54% 9.0%
Analyst Consensus Buy Hold
Investment Thesis
JNJ — Johnson & Johnson
Johnson & Johnson is a leading healthcare company focused on pharmaceuticals and medical devices following its consumer health spin-off. The business quality is high due to its durable competitive moat, diversified portfolio, and strong management with deep institutional knowledge. Despite a 52.4% decline in earnings in the most recent quarter, revenue grew 9.9% year-over-year in the same period,…
QCOM — QUALCOMM Incorporated
Qualcomm Incorporated is a leading semiconductor company specializing in wireless chipsets and IP licensing, with dominant positions in 5G modems via QCT (87% of revenue) and steady QTL royalties. The business excels through a vast patent moat, diversification into automotive and IoT, and robust growth (revenue +13% YoY to $44B in FY2025), but faces risks from Apple modem shifts and China exposur…
Accumulation Zones
Metric JNJ QCOM
Zone Low $191.71 $146.23
Zone High $217.27 $165.73
In Buy Zone? No Yes
← JNJ Research    QCOM Research →    All Research